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comparison with their HLA-identical sibling donor
Abstract
Background. Hematopoietic stem cell transplantation has become an established procedure worldwide.
Severe early and late complications are well described. Little is known about more subtle changes in
general health status of very long term survivors. To assess health status of very long term survivors in
comparison with their respective human leukocyte antigen-identical sibling donors. Design and
methods: Case matched comparison in a cross-sectional cohort performed in a tertiary university
hospital and referral center for hematopoietic stem cell transplantation. Forty four pairs of recipients and
their respective donors with a very long term (17.5 years median; 11-26 years range) follow-up after
allogeneic hematopoietic stem cell transplantation were included. A comparative clinical evaluation and
examination of routine clinical chemistry tests was done. Results. Recipients had more frequently a
lower Karnofsky score (p=0.05), hypertension (p=0.015) and dyslipidemia (p=0.002) but were less
likely to be smokers (0.016). Recipients showed systematically lower glomerular filtration rates
(p<0.0001), higher liver function tests (p=0.0004 for Aspartat-Amino-Transferase) and reduced thyroid
function (p=0.002) despite normal or near normal values and independent of presence or absence of
chronic graft-versus-host disease. Indicators of inflammation were more frequent in recipients (9/44)
with ongoing chronic graft-versus-host disease as measured by higher c-reactive protein (p=0.001) and
higher von Willebrand factor (p=0.002). Conclusions. Clinically very long term survivors after an
allogeneic hematopoietic stem cell transplantation present more frequently with cardiovascular risk
factors and with subtle signs of altered organ function compared to their sibling donors. Even minimal
ongoing chronic graft-versus-host disease remains associated with elevated laboratory indicators of
inflammation. The clinical significance of these findings needs to be defined.
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Background
Hematopoietic stem cell transplantation has become an established procedure worldwide.
Severe early and late complications are well described. Little is known about more subtle
changes in general health status of very long-term survivors. The study objective was to assess
health status of very long-term survivors in comparison with their respective human leukocyte
antigen-identical sibling donors.
Design and Methods
Case matched comparison in a cross-sectional cohort was performed in a tertiary university
hospital and referral center for hematopoietic stem cell transplantation. Forty-four pairs of
recipients and their respective donors with a very long-term (17.5 years median; 11-26 years
range) follow up after allogeneic hematopoietic stem cell transplantation were included.  A
comparative clinical evaluation and examination of routine clinical chemistry tests was carried
out. 
Results
Recipients more frequently had a lower Karnofsky score (P=0.05), hypertension (P=0.015) and
dyslipidemia (P=0.002) but were less likely to be smokers (P=0.016). Recipients showed sys-
tematically lower glomerular filtration rates (P<0.0001), higher liver function tests (P=0.0004
for Aspartat-Amino-Transferase) and reduced thyroid function (P=0.002) despite normal or
near normal values, and independent of presence or absence of chronic graft-versus-host dis-
ease. Indicators of inflammation were more frequent in recipients (9 of 44) with ongoing chron-
ic graft-versus-host disease as measured by higher C-reactive protein (P=0.001) and higher von
Willebrand factor (P=0.002). 
Conclusions
Clinically very long-term survivors after an allogeneic hematopoietic stem cell transplantation
present more frequently with cardiovascular risk factors and with subtle signs of altered organ
function compared to their sibling donors. Even minimal ongoing chronic graft-versus-host dis-
ease remains associated with elevated laboratory indicators of inflammation. The clinical sig-
nificance of these findings needs to be defined.
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Introduction
Allogeneic hematopoietic stem cell transplantation
(HSCT) has become a curative treatment option for a vari-
ety of malignant and non-malignant disorders worldwide.1
Overall survival has improved substantially over the last
decade, and the number of procedures, and consequently
the number of long-term survivors, is continuously
increasing.2 Nevertheless, HSCT remains associated with
considerable early and late treatment-related morbidity
and mortality.3 Pre-transplant patient and donor character-
istics can give a reasonable risk estimate of allogeneic
HSCT.4 Over recent years, the focus has shifted to long-
term survivors. Patients do expect to recover their initial
health status after HSCT and to lead a normal life with
complete social integration. However, when compared to
a matched general population, mortality remains
increased.5 Many late complications, such as secondary
cancer,6-8 cataract development,9,10 infertility,11,12 endocrine
dysfunctions,13 bone and joint degeneration,14,15 and cardio-
vascular and cardiac complications16-18 have been well
described. Other organ dysfunctions have been discussed
but an unequivocal relationship with the transplant proce-
dure remains an open question. In theory, however, any
organ or tissue could be a target. 
Late effects of HSCT can be the consequence of the ini-
tial disease, of pre-transplant comorbidity, of the treat-
ments used before transplantation, of the conditioning
regimen, of acute and chronic graft-versus-host disease
(GVHD) and its treatment or of infectious complications.
Moderate and severe side-effects are easily recognized and
during the first year after allogeneic HSCT anomalies of
laboratory function tests are frequent. When discontinua-
tion of immunosuppressive drugs becomes feasible, most
of these parameters tend to normalize. Little attention is
usually given to discrete changes in clinical chemistry
parameters during follow up. However, changes persisting
over years and decades could eventually lead to significant
late organ dysfunction. We were, therefore, interested in
systematically searching for subtle signs of organ dysfunc-
tion in very long-term survivors of allogeneic HSCT and
used their respective sibling donor as comparator.
Design and Methods
Study design
This was a case matched comparison in a cross-sectional
cohort single center study of the division of Hematology of the
University Hospitals Basel, Switzerland to assess health status,
hematopoietic function and organ alterations in very long-term
survivors after HSCT compared with their respective HLA-iden-
tical sibling stem cell donors. In brief, all recipients transplanted
more than ten years ago from an HLA-identical sibling donor,
living in the region and still in complete remission at the last fol-
low up were invited to present together with his or her sibling
donor on the same day to our outpatient clinic. All donors and
recipients gave written informed consent. The study was
approved by the Beider Basel Ethics Committee.
Patient population
From 82 pairs contacted, 44 (54%) agreed to participate in the
study. There were no differences in characteristics between those
pairs included in the study compared to those not included. The
characteristics of the recipients and their respective donors evalu-
ated in this study are summarized in Table 1. The transplant had
been performed 11 to 26 years (median 17.5 years) earlier. There
were slightly more male recipients (55%) and slightly more
female donors (55%) (P=0.55) with no difference in age between
donors and recipients. Slightly more recipients presented with a
Karnofsky score below 100 (P=0.05; c2 test).
Total body irradiation (TBI) was part of the conditioning for 39
(89%) of the recipients. Of these, acute GVHD was observed in 26
(59%) and chronic GVHD in 22 (50%). Through the follow up of
this cohort, chronic GVHD affected the following organs: skin
n=13 recipients, oral mucosa n=11, eye n=6, vagina n=4, liver n=3,
gastrointestinal n=2, lung n=1. At time of study, 9 recipients had
ongoing chronic GVHD (oral mucosa n=6, vagina n=4, skin n=3,
liver n=2 and lung n=1) and 6 recipients were still under immuno-
suppressive therapy (cyclosporine n=4, prednisone n=1,
cyclosporine and prednisone n=1, mycophenolate mofetil n=1). 
Examinations
A complete clinical and biological examination was performed
for both the recipient and the donor. In order to assess the gen-
eral health status, all participants were asked to fill in a standard-
ized questionnaire: the Short Form 36 (SF-36) Health Survey for
quality of life assessment.19-21 Moreover, all participants filled in
a detailed questionnaire focused on organ symptoms, past and
current diseases, and current medication. For most participants,
we also received full medical information from the primary care
physician. The evaluated biological parameters included a com-
Table 1. Characteristics of recipients and donors.
                                                                           Recipients        Donors
                                                                               N=44              N=44
Sex
Female                                                                         20 (45.5%)       24 (54.5%)
Male                                                                             24 (54.5%)       20 (45.5%)
Median age at HSCT, years (range)                          26.8 (5-50)      25.8  (2-46)
Median age at the examination, years (range)     44.3 (24-63)     43.4(22-61)
Median follow up after HSCT, years (range)         17.5 (11-26)
Diagnosis
Severe aplastic anemia                                                   4 (10%)
Hematologic malignancies                                            40 (90%)
Acute myeloblastic leukemia                                   16 (36%)
Chronic myeloid leukemia                                       11 (25%)
Acute lymphoblastic leukemia                                 7 (16%)
Non-Hodgkin’s lymphoma                                          3 (7%)
Chronic lymphocytic leukemia                                  1 (2%)
Myelodysplastic syndrome                                         2 (4%)
TBI
yes/no                                                                    39 (89%)/5 (11%)
TBI fractionated/non-fractionated                28 (70%)/11 (30%)
Source of stem cells: bone marrow                              100%
Median nucleated cell dose infused (x108/kg)    4.2 (0.3-16.6) 
Acute GVHD
none or grade I /grade II-IV                            18 (41%)/ 26 (59%)
Chronic GVHD                                                                          
none/yes                                                              22 (50%)/ 22 (50%)
Still on immunosuppression /ongoing                        6/9
cGVHD
Karnofsky score
100%                                                                             38 (86.4%)       43 (97.7%)
≤90%                                                                             6 (13.6%)          1 (2.3%)
plete blood count with lymphocyte subpopulations and telom-
ere length determination as published elsewhere.22 For the pres-
ent study, we carried out paired analysis to compare the results
of the routine clinical chemistry tests including inflammatory
parameters (C-reactive protein (CRP), albumin, von Willebrand
factor antigen (vWF), liver tests (bilirubine, ASAT, ALAT,
Gamma-GT), renal function (creatinine, glomerular filtration
rate), serum lipids (triglycerides, cholesterol, HDL-cholesterol,
LDL-cholesterol, cholesterol/HDL-cholesterol ratio), and thyroid
function (TSH). Moreover, pre-transplant values for renal func-
tion evaluation were collected from the donors’ and recipients’
clinical files; results before starting conditioning were considered
as pre-transplant values. 
Statistical analysis
To compare clinical chemistry values between recipients and
their respective donors, as well as pre-treatment and current
data, we used the non-parametric Wilcoxon’s Signed Rank Test.
Diagnosis and staging of chronic GVHD were assessed accord-
ing to NIH consensus criteria.23 To evaluate the impact of chron-
ic GVHD, a comparison between recipients with and recipients
without chronic GVHD, and between donors and recipients
with and without chronic GVHD was performed. We consid-
ered the constellation of a significant difference between donors
and recipients with chronic GVHD without a significant differ-
ence between donors and recipients without chronic GVHD as
an indicator for an impact of chronic GVHD on the respective
laboratory value. In any other constellation we considered that
chronic GVHD could not be the unique factor involved. 
The interactions between risk factors and clinical chemistry
parameters were evaluated using linear regression analysis.
Differences between the results of comparative tests were consid-
ered significant if the two-sided P value was less than 0.05.
Statistical analysis was performed using SPSS statistical software
(SPSS for Windows, Release 17, SPSS, Inc., Chicago, Illinois, USA).
Results
There were significant differences between donors and
recipients regarding the absolute values of the individual
laboratory function tests, regarding the percentage of
abnormal values, and regarding the evolution from pre-
transplant values to time of follow up.
Recipients showed a decreased kidney function with
systematically higher creatinine levels and systematically
lower GFR than their donors (P<0.001), had systematically
higher liver function tests values (Figure 1A) except for
bilirubin (for respective P values see Table 2) and system-
atically higher TSH values (P=0.002) independent of pres-
ence or absence of chronic GVHD (Table 2). This was also
reflected by a significantly higher number of abnormal
GFR (9% vs. 0%; P=0.041) and abnormal liver function
tests (23% vs. 7% for ASAT; P=0.035). There was no dif-
ference in laboratory signs of inflammation and for total
cholesterol, LDL- and HDL-cholesterol between donors
and recipients without chronic GVHD. Interestingly,
recipients without chronic GVHD had higher triglycerides
(P=0.007) and a higher cholesterol/HDL ratio (P=0.047)
than their respective donors.
In contrast, recipients with ongoing chronic GVHD
more frequently had laboratory signs of inflammation and
significantly higher CRP (P=0.001) (Figure 1B) and vWF
(P=0.002), and significantly lower albumin values
(P=0.021) (Table 2). 
Organ dysfunction, defined as two or more laboratory
values out of normal range (Table 2) for CRP, GFR, albu-
min, vWF, liver tests or dyslipidemia, was significantly
more frequent in recipients (28 of 44; 64%) than in donors
(7 of 44; 16%) (P<0.0001); this was due to the higher rate
of organ dysfunction in recipients with (13 of 22; 59%)
than without (5 of 22; 23%) chronic GVHD (P=0.014). 
At time of transplantation, there was no difference in
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Figure 1. Laboratory values of 44 recipients and their respective
HLA-identical sibling donors 17.5 years (median) after an allogeneic
HSCT. Figure presents median and 75% confidence interval for
donors (blue) and recipients (red). (A) The figure illustrates the liver
function test for ASAT and presents results globally (red left) and
subdivided in recipients with and without chronic GVHD. Data reflect
an example with a systematic elevation in recipients, independent
of presence or absence of chronic GVHD. (B) The figure illustrates
the CRP values and presents results globally (red left) and subdivid-
ed in recipients with and without chronic GVHD. Data reflect an
example with a systematic elevation in recipients with ongoing
chronic GVHD. (C) The figure illustrates the glomerular filtration
rates (GFR) in donors and recipients at time of HSCT and at time of
follow up. Data reflect the systematic decrease of GFR in recipients
since time of transplant and the stable values in donors.   
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GFRs of donors and recipients (P=0.1) and GFRs of donors
did not change over time (P=0.138). In contrast, as men-
tioned above, GFRs of recipients declined significantly
over time (P=0.02). Consequently, at study time, there
were significant differences in GFR between recipients
and their respective donors (P<0.0001) (Figure 1C).
Significantly more recipients presented with arterial
hypertension (22 of 44 vs. 11 of 44; P=0.015) and dyslipi-
demia (27 of 44 vs. 13 of 44; P=0.002) but more donors
reported a history of cigarette smoking (P=0.016). There
was no difference in diabetes, body mass index (BMI),
continuous cigarette smoking since HSCT, and physical
activity. Recipients were significantly more often treated
for their hypertension (16 of 22; 73%) when compared to
donors (4 of 11; 36%: P=0.044). In contrast, only 5 of 27
(18%) of the recipients and 3 of 13 (23%) of the donors
were treated for dyslipidemia (P=0.736) independent of
immunosuppression status of the recipients. At time of
study, 25 of 44 (75%) recipients reported regular physical
activity and 9 of 44 (20%) still continued smoking. 
No familiar predisposition for cardiovascular risk factors
could be identified in this small series. Arterial hyperten-
sion was observed 17 times in recipients only, 6 times in
donors only, and 5 times in both recipient and donor.
Dyslipidemia was found in 19 recipients, in 4 donors, and
in 8 pairs. Four recipients and one donor had developed an
arterial event since time of HSCT.
Discussion
Data from this unique cohort of very long-term sur-
vivors after allogeneic HSCT show a consistent difference
in the number of biologically relevant laboratory values
between recipients and their respective stem cell donor
(Table 2). The recipients, at a similar median age, showed
systematically lower glomerular filtration rates, higher
liver function tests, reduced thyroid function, higher levels
of indicators for inflammation and higher serum lipid lev-
els. These differences were subtle but significant. Most of
the recipients had normal or near normal values with only
a small proportion out of the reference range. The abnor-
malities of inflammatory parameters, CRP, vWF antigen
and albumin were related to a history of chronic GVHD;
the differences in renal, liver and thyroid function and
serum lipid tests were not explained by chronic GVHD. 
Severe late organ complications after HSCT such as
chronic kidney disease,24,25 liver complications or
endocrine dysfunction13 have been well described.
Moreover, long-term survivors of HSCT remain at an
increased risk of developing metabolic syndrome, dia-
betes, dyslipidemia, and hypertension compared to sibling
donors. In a cross sectional study, a high prevalence of
metabolic syndrome and elevated triglycerides was
reported among adult survivors of allogeneic HSCT com-
pared with a general population.26,27 Another study
Table 2. (Left) Number of recipients/donors with abnormal values in respect to reference values. (Right) Clinical chemistry parameters: comparison
between long-term survivors and their respective donor (with and without GVHD).
Parameter N. of recipients/donors with abnormal values Recipients P values donors
in respect to reference values versus recipients
                                  All            Donors  recipients    P value#          Donors                 All               With GVHD     Without GVHD             All           With/without
                                n=88            n 44         n=44                                 n=44                 n=44                  n=22                 n=22              recipients           GVHD
Inflammatory parameters
CRP*                       10 (11%)         4 (9%)      6 (14%)           0.502          1.0 (0.5-38.1)      3.7 (0.5-79.2)       4.5 (0.9-79.2)       1.2 (0.5-11.0)               0.034              0.001/0.125
vWF**                    18 (21%)         4 (9%)     14 (33%)          0.020          97.5 (55-188)       126 (51-296)        139 (51-296)        108 (51-235)               0.006              0.002/0.173
Albumin                  9 (10%)          2 (4%)      7 (16%)           0.079             41 (29-46)           40 (31-45)            38 (31-43)            40 (32-45)                  0.009              0.021/0.361
Kidney function
Creatinine               3 (3%)                 0             3 (7%)            0.078             66 (45-93)          79 (44-206)          88 (55-206)          77 (44-103)               0.0001          <0.0001/0.007
GFR***                    4 (4%)                 0            4  (9%)           0.041           107 (72-144)        82 (30-141)          77 (30-124)          95 (66-141)              <0.0001         <0.0001/0.034
Liver function
Bilirubine                1 (1%)           1 (2%)             0                 0.500             9.5 (5-29)            8.0 (5-20)             8.0 (5-17)             7.0 (5-20)                  0.020              0.213/0.053
ASAT                       13 (15%)         3 (7%)     10 (23%)          0.035            22  (16-64)         27.5 (15-65)           26 (20-65)            28 (15-44)                0.0004             0.002/0.013
ALAT                       12 (14%)         4 (9%)      8 (18%)           0.214            22 (10-101)         25.5 (12-72)           27 (12-70)            23 (12-72)                  0.037              0.030/0.161
Gamma-GT              8 (9%)           1 (2%)      7 (16%)           0.024             18 (9-140)          31 (10-319)          30 (11-319)           32 (10-91)                0.0003             0.002/0.005
Alkaline                    6 (7%)           1 (2%)      5 (11%)           0.091            56 (32-155)         69 (39-222)          70 (39-222)          68 (41-120)                0.003              0.016/0.034
Phosphatase
Lipids
Tryglicerides         29 (33%)       10 (23%)   19 (43%)          0.041          1.0 (0.45-3.9)      1.5 (0.53-8.9)       1.5 (0.53-8.9)       1.6 (0.69-3.7)               0.011              0.208/0.007
Cholesterol           33 (38%)       11 (26%)   22 (50%)          0.019           4.7 (3.1-9.3)        5.1 (2.7-7.8)         5.0 (2.7-7.8)         5.3 (3.7-6.4)                0.118              0.407/0.058
HDL-cholesterol    2 (2%)                 0             2 (4%)            0.153           1.6 (1.0-3.2)        1.5 (0.6-2.5)         1.5 (0.6-2.5)         1.5 (1.0-2.2)                0.037              0.213/0.124
Chol/HDL-chol.      8 (9%)           1 (2%)      7 (16%)           0.029           2.9 (1.7-8.6)        3.2  (1.8-8.7)         3.1 (1.8-8.7)         3.4 (1.8-5.7)                0.022              0.094/0.047
Ratio                               
LDL-cholesterol    8 (9%)          6 (13%)      2 (4%)            0.138           2.4  (1.4-7.7)       2.8 (1.07-4.8)        2.7 (1.1-4.8)         2.9 (1.1-3.9)                0.126              0.284/0.145
Thyroid function
TSH                           8 (9%)           1 (2%)      7 (16%)            0.26          1.6 (0.52-5.11)   2.3 (0.04-30.33)  2.36 (0.08-30.33)  2.21 (0.04-9.20)             0.002              0.012/0.010
*C-reactive protein; ** von Willebrand factor antigen; ***Glomerular Filtration Rate; # Wilcoxon’s rank test.
revealed a high proportion of undiagnosed or untreated
cardiovascular risk factors.28 According to the interpreta-
tion of the authors, physicians seemed to be reluctant to
initiate a treatment for cardiovascular risk factors, possibly
in the expectation that diabetes, dyslipidemia or hyperten-
sion would improve or disappear upon discontinuation of
immunosuppressive treatment. We confirm and extend
these findings. Cardiovascular risk factors and the threats
for cardiovascular complications do persist after immuno-
suppression is discontinued. Even though most recipients
were correctly treated for their arterial hypertension, this
was not the case for dyslipidemia: among all recipients
who fulfilled the criteria for dyslipidemia less than 20%
were treated accordingly.29 Furthermore, smoking was still
an issue despite repeated medical advice to stop. 
These concerns are substantiated by our findings of dis-
crete but systematic biological changes in otherwise
apparently healthy long-term survivors. We followed with
this new approach of evaluation after HSCT, the concept
derived from general population studies. Indeed, increased
CRP values, even within the normal range were shown to
enhance the global coronary risk as assessed by the
Framingham Score30 or to be associated with an increased
risk of death due to chronic diseases.31 Likewise, serum
cholesterol concentrations even within the so called nor-
mal range have been directly related to morbidity for coro-
nary heart disease.32 Therefore, increased, but near normal
clinical chemistry values might indicate an ongoing risk
for the premature cardiovascular disease after allogeneic
HSCT. This might relate to patients with and without
chronic GVHD. So far, no clear relationship has been
demonstrated between cardiovascular complications and
chronic GVHD. Still, an alloreactive effect seems to play a
role; recipients treated with allogeneic compared to autol-
ogous HSCT suffer significantly more frequently from
such complications.33 It is, therefore, of interest that an
inflammatory state was observed more frequently in
patients with chronic GVHD. Abnormal values of clinical
chemistry parameters, such as CRP or serum lipids, could
help to detect patients at risk and to initiate preventive
strategies. 
The systematic decrease in GFR in all recipients, with or
without chronic GVHD fits with this concept. Multiple
mechanisms can explain chronic renal dysfunction in
recipients of allogeneic HSCT. They have been treated
with intensive conditioning with or without TBI, have
been exposed to multiple drug toxicities, and have suf-
fered from acute and chronic GVHD and infectious com-
plications.23,24 The metabolic syndrome with its associated
microalbuminuria could enhance the premature aging in
the endothelial compartment and renal vascular network,
as has been demonstrated for hematopoietic cells.22 The
numbers of patients examined in our series were too small
to document such an association.
What are the consequences of these findings of subtle
altered organ function in otherwise apparently clinically
healthy very long-term survivors after HSCT? Clearly, the
clinical consequences of these findings, of their early
detection and of the introduction of therapeutic measures
have to be assessed in a larger group of patients. These
results demonstrate that individuals undergoing allogeneic
HSCT, even when cured, will never become “non-
patients”. Allogeneic HSCT is a lifelong commitment for
all involved: the patient, his or her family, the primary care
physician, the transplantation team, and the healthcare
providers.
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